Congressional Testimony
This section includes testimony by FDA officials before House and Senate Committees and Subcommittees. For testimony from previous years, see the FDA Archive.
Date | Testimony | Speaker | Excerpt |
---|---|---|---|
Evaluating FDA Human Foods and Tobacco Programs - 09/10/2024 | Jim Jones, Brian King | ||
Combatting The Youth Vaping Epidemic By Enhancing Enforcement Against Illegal E-Cigarettes - 06/12/2024 | Brian King | ||
Check Up: Examining FDA Regulation of Drugs, Biologics, and Devices - 05/22/2024 | Patrizia Cavazzoni,, Peter Marks, Jeff Shuren | ||
Oversight of the U.S. Food and Drug Administration - 04/11/2024 | Robert Califf | ||
Assessing America's Vaccine Safety Systems, Part 1 - 02/15/2024 | Peter Marks | ||
FDA Oversight Part II: Responsibility for the Infant Formula Shortage - 05/11/2023 | |||
Preparing for and Responding to Future Public Health Risks - 05/11/2023 | Robert Califf | ||
Preparing for the Next Public Health Emergency: Reauthorizing the Pandemic and All-Hazards Preparedness Act - 05/04/2023 | Robert Califf | ||
Reauthorization of the Animal Drug User Fee Programs - 03/30/2023 | Tracey Forfa | ||
The Federal Response to COVID-19 - 02/08/2023 | Robert Califf |